Wall Street analyst estimates for CalciMedica, Inc. (CALC): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
CalciMedica, Inc., a clinical-stage biotechnology company headquartered in La Jolla, California, is focused on creating treatments for life-threatening inflammatory diseases that currently lack adequate therapies. The company's proprietary approach involves blocking calcium release-activated (CRAC) channels, a mechanism designed to modulate the immune system and protect against cellular and tissue damage in these severe conditions.
Recent Earnings Surprises
| Date | EPS Actual | EPS Est. | vs Est. |
|---|---|---|---|
| 2026-11-11 | $-1.27 | ||
| 2026-08-11 | $-2.25 | $-1.43 | -57.9% |
| 2026-05-13 | $-1.50 | $-1.40 | -7.1% |
| 2026-03-26 | $-3.40 | $-2.75 | -23.6% |
| 2025-11-12 | $-2.60 | $-2.06 | -26.1% |
| 2025-08-11 | $-2.00 | $-2.00 | +0.0% |
| 2025-05-14 | $-1.80 | $-2.15 | +16.3% |
| 2025-03-27 | $-0.34 | $-0.48 | +29.2% |
Valuation Ratios
| Price / Book | -14601.07 |
| EV / EBITDA | -3521.14 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | $175000 | $303000 | $395000 | $519000 | 0 | 0 | 0 | $46000 |
| Gross Profit | -$175000 | -$303000 | -$395000 | -$519000 | 0 | 0 | 0 | -$46000 |
| Research & Development | $23.0M | $30.6M | $21.0M | $18.9M | $8.3M | $15.9M | $14.5M | $15.2M |
| Selling, General & Admin | $5.6M | $6.6M | $8.9M | $17.0M | $5.8M | $22.2M | $9.7M | $7.9M |
| Operating Expenses | $28.6M | $37.2M | $29.4M | $35.4M | $14.2M | $38.1M | $24.2M | $23.1M |
| Operating Income | -$28.6M | -$37.5M | -$29.8M | -$35.9M | -$14.2M | -$38.1M | -$24.2M | -$23.1M |
| EBITDA | -$28.2M | -$36.7M | -$27.1M | -$35.3M | -$7.6M | -$34.2M | -$13.6M | -$28.1M |
| Interest Expense | 0 | 0 | $143000 | $126000 | $132000 | $110000 | 0 | $1.4M |
| Pre-tax Income | -$28.4M | -$37.0M | -$27.5M | -$35.8M | -$7.8M | -$34.4M | -$13.7M | -$29.6M |
| Income Tax | $13859 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | -$28.4M | -$37.0M | -$27.5M | -$35.8M | -$7.8M | -$34.4M | -$13.7M | -$29.6M |
| EPS | $-165.50 | $-179.25 | $-367.50 | $-118.30 | $-116.00 | $-38.25 | $-6.10 | $-9.85 |
| EPS (Diluted) | $-165.50 | $-179.25 | $-367.50 | $-118.30 | $-116.00 | $-38.25 | $-6.10 | $-9.85 |
| Shares Outstanding (Diluted) | $171456 | $206619 | $94549 | $302847 | $306990 | $898000 | $2.2M | $3.00B |
Price
| Price | $1.98 |
| Market Cap | $6M |
| Exchange | NASDAQ |
| Country | US |
Related companies: ATNM · ELUT · LTRN · LVTX · MAIA · PDSB · RNXT
Explore sector: Healthcare · Biotechnology
More sections of CALC: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks